An analog of abatacept with higher affinity for CD80 and CD86 named belatacept was successfully used in phase III clinical trials for kidney transplant recipients, and was approved by the US Food and Drug Administration as therapeutic molecule for this indication in 2011 (65–67). Here, CD86 is linked to medical procedure.